Traditional medicines are an integral part of health care worldwide, even though their efficacy has not been scientifically proven. HIV-infected individuals may use them singularly or in combination with conventional medicines. Many in vitro studies have proven the anti-HIV, anti-Candida, and anti–herpes simplex virus potential of traditional plants and identified some of the mechanisms of action. Very few in vivo studies are available that involve a small number of participants and show controversial results. In addition, knowledge is limited of the role of traditional medicines in the enhancement of the immune system. The use of traditional medicines with antiretroviral drugs (ARVs) has created a problem because drug interactions compromise the efficacy of ARVs. Several currently popular plants have been studied in the laboratory for their interaction with ARVs, with disadvantageous results. Unfortunately, no clinical trials are available. The science of traditional medicines is relatively new and is at present being modernized worldwide. However, there are still ethical issues regarding traditional medicines that need to be addressed—for example, regulations regarding quality control and standardization of medicines, regulation and education of healers who deliver these medicines, and unregulated clinical trials. The workshop addressed the following questions about traditional medicine and their use in HIV infection: What are the mechanisms of action of anti-HIV traditional medicines? Should traditional medicines be used in conjunction with ARV? Do traditional medicines enhance the immune system? Should medicinal plants be used for the control of oral infections associated with HIV? What are the ethical issues surrounding the use of traditional medicines for the treatment of HIV and associated infections?
AbramsDIKunoSWongRJeffordsKNashMMolaghanJB. (1989). Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med110:183-188.
2.
BessongPOObiCLAndréolaMRojasLPouységuLIgumborE. (2005). Evaluation of selected South African medicinal plants for inhibitory properties against human immunodeficiency virus type 1 reverse transcriptase and integrase. J Ethnopharmacol99:83-91.
3.
BodekerGCarterGBurfordGDvorak-LittleM (2006). HIV/AIDS: traditional systems of health care in the management of a global epidemic. J Altern Complement Med12:563-576.
4.
BoraPCBokilAHiraSGharpureM (1996). Efficacy of ayurvedic formulation among HIV-infected persons [abstract 4101]. Int Conf AIDS11:269.
5.
BrownLHeynekeOBrownDvan WykJPHammanJH (2008). Impact of traditional medicinal plant extracts on antiretroviral drug absorption. J Ethnopharmacol119:588-592.
6.
BurackJHCohenMRHahnJAAbramsDI (1996). Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. J Acqir Immune Defic Syndr Hum Retrovirol12:386-393.
7.
BurnettABaggaleyRNdovi-MacMillanMSulweJHang’ombaBBennettJ (1999). Caring for people with HIV in Zambia: are traditional healers and formal health workers willing to work together?AIDS Care11:481-491.
8.
ChenHM (2007). Zoster Chinese medicine treatment. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi21:285-7.
9.
CohlyHHAsadSDasSKAngelMFRaoM (2003). Effect of antioxidant (turmeric, turmerin and curcumin) on human immunodeficiency virus. Int J Mol Sci4:22-33.
10.
CosPMaesLVlietinckAPietersL (2008). Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection: an update (1998-2007). Planta Med74:1323-1337.
11.
CreaghTRuckleJLTolbertDTGiltnerJEiznhamerDADuttaB. (2001). Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother45:1379-1386.
12.
De ClercqE (2000). Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev20:323-349.
13.
de MaatMMHoetelmansRMMath tRAvan GorpECMeenhorstPLMulderJW. (2001). Drug interaction between St John’s wort and nevirapine. AIDS15:420-421.
14.
FlexnerCBarditch-CrovoPAKornhauserDMFarzadeganHNerhoodLJChaissonRE. (1991). Pharmacokinetics, toxicity and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother35:2544-2550.
15.
FosterBCFosterMSVenderhoekSKrantisABudzinskiJWArnasonJT. (2001). An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci4:176-184.
16.
FranzblauSGCrossC (1986). Comparative in vitro antimicrobial activity of Chinese medicinal herbs. J Ethnopharmacol15:279-288.
17.
GowdeyGLeeRKCarpenterWM (1995). Treatment of HIV-related hairy leukoplakia with podophyllum resin 25% solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod79:64-67.
18.
GulickRMMcAuliffeVHolden-WiltseJCrumpackerCLiebesLSteinDS. (1999). Phase I studies of hypericin, the active compound in St John’s Wort, as an antiretroviral agent in HIV-infected adults: AIDS clinical trial group protocols 150 and 258. Ann Intern Med16:510-514.
19.
GurleyBJGardnerSFHubbardMAWilliamsDKGentryWBCuiY. (2002). Cytochrome P450 phenotypic ratio for predicting herb-drug interactions in humans. Clin Pharmacol Ther72:276-287.
20.
HamzaOJvan den Bout-van den BeukelCJMateeMIMoshiMJMikxFHSelemaniHO. (2006). Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. J Ethnopharmacol108:124-132.
21.
HanYWangYLiuYZhaoWLiJXingH. (2009). Influence of different antiretroviral and traditional therapies on the oral manifestations of AIDS/HIV. Poster presentation at Sixth World Workshop on Oral Health and Diseases in AIDS, Beijing, China. http://www.hivdent.org/6thWWOHDA/6WWOHDA_IDATTO.htm. Accessed October 27, 2010.
22.
KayomboEJUisoFCMbwamboZHMahunnahRLMoshiMJMgondaYH (2007). Experience of initiating collaboration of traditional healers in managing HIV and AIDS in Tanzania. J Ethnobiol Ethnomed3:6.
23.
KhanMTAtherAThompsonKDGambariR (2005). Extracts and molecules from medicinal plants against herpes simplex viruses. Antiviral Res67:107-119.
24.
KimHJWooERShinCGParkH (1998). A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J Nat Prod61:145-148.
25.
KisangauDPLyaruuHVHoseaKMJosephCC (2007). Use of traditional medicines in the management of HIV/AIDS opportunistic infections in Tanzania: a case in the Bukoba rural district. J Ethnobiol Ethnomed3:29.
26.
KitamuraKHondaMYoshizakiHYamamotoSNakaneHFukushimaM. (1998). Baicalin, an inhibitor of HIV-1 production in vitro. Antiviral Res37:131-140.
27.
KusumMKlinbuayaemVBunjobMSangkitpornS (2004). Preliminary efficacy and safety of oral suspension SH, combination of five Chinese medicinal herbs, in people living with HIV/AIDS; the phase I/II study. J Med Assoc Thai87:1065-1070.
28.
LavieGValentineFLevinBMazurYGalloGLavieD. (1989). Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci U S A86:5963-5967.
29.
LeeLSWiseSDChanCParsonsTLFlexnerCLietmanPS (2008). Possible differential induction of phase 2 enzyme and antioxidant pathways by American ginseng, Panax quinquefolius. J Clin Pharmacol48:599-609.
30.
LiuJPManheimerEYangM (2005). Herbal medicines for treating HIV infection and AIDS. Cochrane Database Syst Rev3:CD003937.
31.
MillsEFosterBCvan HeeswijkRPhillipsEWilsonKLeonardB. (2005). Impact of African herbal medicines on antiretroviral metabolism. AIDS19:95-97.
32.
MotseiMLLindseyKLvan StadenJJägerAK (2003). Screening of traditionally used South African plants for antifungal activity against Candida albicans. J Ethnopharmacol86:235-241.
33.
NolkemperSReichlingJStintzingFCCarleRSchnitzlerP (2006). Antiviral effect of aqueous extracts from species of the Lamiaceae family against Herpes simplex virus type I and type 2 in vitro. Planta Med72:1378-1382.
34.
NyikaA (2006). Ethical and regulatory issues surrounding African traditional medicine in the context of HIV/AIDS. Dev World Bioeth7:25-34.
35.
PatelMGulubeZDuttonM (2009). The effect of Dodonea viscosa var. angustifolia on Candida albicans proteinase and phospholipase production and adherence to oral epithelial cells. J Ethnopharmacol124:562-565.
36.
PomerantzRJHornDL (2003). Twenty years of therapy for HIV-1 infection. Nat Med9:867-873.
ReutrakulVNingnuekNPohmakotrMYoosookCNapaswadCKasisitJ. (2007). Anti-HIV-1 flavonoid glycosides from Ochna integerrima. Planta Med73:683-688.
39.
RowleyDCHansenMSRhodesDSotrifferCANiHMcCammonJA. (2002). Thalassiolins A-C: new marine-derived inhibitors of HIV cDNA integrase. Bioorg Med Chem10:3619-3625.
40.
RudolphMJOgunbodedeEOMistryM (2007). Management of the oral manifestations of HIV/AIDS by traditional healers and care givers. Curationis30:56-61.
41.
RunyoroDKNgassapaODMateeMIJosephCCMoshiMJ (2006a). Medicinal plants used by Tanzanian traditional healers in the management of Candida infections. J Ethnopharmacol106:158-165.
42.
RunyoroDKMateeMINgassapaODJosephCCMbwamboZH (2006b). Screening of Tanzanian medicinal plants for anti-Candida activity. BMC Complement Altern Med6:11.
43.
SangkitpornSShideLKlinbuayaemVLeenasirimakulPWirayutwatthanaNALeechanachaiP. (2005). Efficacy and safety of Zidovudine and Zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Southeast Asian J Trop Med Public Health36:704-708.
44.
SasakiHTakeiMPollardRBSuzukiF (2002). Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients. Pathobiology70:229-236.
45.
SeneviratneCJWongRWSamaranayakeLP (2007). Potent anti-microbial activity of traditional Chinese medicine herbs against Candida species. Mycoses51:30-34.
46.
ShaunakSThorntonMJohnSTeoIPeersEMasonP. (1998). Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulfate in patients with AIDS. AIDS12:399-409.
47.
ToloFMRukungaGMMuliFWNjagiENKumonKMungaiGM. (2006). Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus. J Ethnopharmacol104:92-99.
48.
TshibanguKCWorkuZBde JonghMAvan WykAEMokwenaSOPeranovicV (2004). Assessment of effectiveness of traditional herbal medicine in managing HIV/AIDS patients in South Africa. East Afr Med J81:499-504.
49.
UsiaTIwataHHiratsukaAWatabeTKadotaSTezukaY (2006). CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants. Phytomedicine13:67-73.
50.
van den Bout-van den BeukelCJHamzaOJMoshiMJMateeMIMikxFBurgerDM. (2008). Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infections. Basic Clin Pharmacol Toxicol102:515-526.
51.
WatsonKGooderhamNJDaviesDSEdwardsRJ (1999). Interaction of the transactivating protein HIV-1 Tat with sulphated polysaccharides. Biochem Pharmacol57:775-83.
52.
WeberRChristenLLoyMSchallerSChristenSJoyceCR. (1999). Randomized, placebo-controlled trial of Chinese herb therapy for HIV-1 infected individuals. J Acquir Immune Defic Syndr22:56-64.
53.
WhiteELChaoWRRossLJBorhaniDWHobbsPDUpenderV. (1999). Michellamine alkaloids inhibit protein kinase C. Arch Biochem Biophys365:25-30.
54.
XuHXWanMDongHButPPFooLY (2000). Inhibitory activity of flavonoids and tannins against HIV-1 protease. Biol Pharm Bull23:1072-1076.
55.
YaoWHZhaoWWuYWZhaoHWeiHXChengC. (2006). Effect of compound glycyrrhizin on peripheral T-lymphocyte subset in AIDS patients. Zhonghua Nan Ke Xue12:598-601.
56.
ZhanLYueSTXueYXAtteleASYuanCS (2000). Effects of qian- kun-nin, a Chinese herbal medicine formulation, on HIV positive subjects: a pilot study. Am J Chin Med28:305-312.
57.
ZhaoJBenLHWuYLHuWLingKXinSM. (1999). Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors. J Exp Med190:101-111.
58.
ZhouSFXueCCYuXQLiCWangG (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit29:687-710.
